Navigation Links
Cancer cell line developed that is resistant to new cancer therapy
Date:12/11/2007

A cancer cell line that is resistant to one of the newest classes of cancer treatments has been developed by researchers who already are using it to determine what else to give patients when this happens.

The ultimate goal is to be able to understand how cancer cells develop resistance and to have forward-thinking strategies about how to combat that resistance, says Dr. Warren Fiskus, postdoctoral fellow in the laboratory of Dr. Kapil Bhalla, director of the Medical College of Georgia Cancer Center.

Resistant cells emerged by treating human leukemic cells with regular, increasing doses of histone deacetylase, or HDAC, inhibitors, similar to what patients would receive. At each dose level, there were some cells that did die, says Dr. Fiskus. Ultimately, we isolated a population of cells that were resistant to very high concentrations of these agents and other agents in the same class.

Dr. Fiskus is presenting the findings Dec. 11 during the American Society of Hematologys 49th Annual Meeting and Exposition in Atlanta.

They found the HDAC inhibitor-resistant cell line resistant to many therapies, including more standard treatment such as chemotherapy, but highly sensitive to heat shock protein 90, or hsp90, inhibitors, another emerging cancer treatment.

As part of their resistance mechanisms, they acquired greater sensitivity to hsp90 inhibitors, says Dr. Bhalla, Cecil F. Whitaker Jr., M.D./Georgia Research Alliance Eminent Scholar in Cancer. This creates a potential combination that can be tested in mouse models and ultimately clinical trials.

HDAC and hsp90 inhibitors are both being studied in combination with other cancer therapies but not each other. However the MCG researchers, who already have published work indicating a synergistic effect, were not surprised by what they found.

Resistance to HDAC inhibitors is going to emerge, so you need a cellular model to understand mechanisms of resistance and an in vivo model, a mouse model typically, to test new combinations you design based on studies in culture, says Dr. Bhalla.

The researchers have put the cell line into a mouse model and other scientists already are asking for the resistant cell line, he says.

This particular cell line can be used to really look at newer agents and new combinations in vitro and in vivo and see if they are safe and effective together, Dr. Fiskus says.

Heat shock proteins are protein caretakers, activating genes that ultimately make proteins, move them around cells and fold them into shape for proper function. Misfolded proteins can cause cancer.

MCG is participating in an early-phase clinical trial of the oral HDAC inhibitor, LBH589, developed by Novartis Corp. Studies also are underway for some innovative uses of hsp90 inhibitors, including Dr. John Catravas studies of its potential as an anti-angiogenesis agent and Dr. Abdullah Kutlars studies to see if it can reduce morbidity and related lung problems in sickle cell disease by suppressing inflammation.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia  
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer cell line developed that is resistant to new cancer therapy
(Date:5/24/2016)... ... ... the #perioddrama campaign to mark Menstrual Hygiene Day on May 28 and raise awareness of ... have access to a toilet, even when they’re on their periods. , WaterAid asked over ... results help shine a light on the awkwardness that women face while menstruating, even in ...
(Date:5/24/2016)... MA (PRWEB) , ... May 24, 2016 , ... ... Harvard Medical School, today announced a licensing relationship that will deliver a new ... This relationship will put the medical knowledge and expertise of Harvard Medical ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... of safety signs and safety labels , has been featured ... Symbols: Laser Labels.” , The eiXtra e-newsletter provides electroindustry professionals with manufacturer, regulatory, ...
(Date:5/24/2016)... Conn. (PRWEB) , ... May 24, 2016 , ... After ... . He spent the next decade in hospitals, on medication, living on Social Security ... Look at the Illness and How I Beat It!” (published by Balboa Press), Alexander ...
(Date:5/24/2016)... ... May 24, 2016 , ... Design Concepts , ... Centro del Quinto Sol Wheel Park’ in Pueblo, Colorado. This park was designed ... something special for this often overlooked neighborhood. Located at 609 E. 6th Street, ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... The World Health Organization (WHO) expanded the Intended ... adolescents aged 13 years, and above. Effective immediately, the PrePex ... and adolescent males in the 14 priority countries in Southern ... first male circumcision device to receive WHO Prequalification on 31 ... said: " The expanded use of PrePex ...
(Date:5/23/2016)... -- Gamida Cell, a leader in cellular ... orphan genetic diseases, announced today it has been awarded ... Israel Innovation Authority (formerly the Office of the Chief ... The mission of the Israel Innovation Authority is to ... and technology, while stimulating economic growth. The ...
(Date:5/22/2016)... DUBLIN , May 23, 2016 ... to develop its anti-fibrotic and anti-inflammatory compound DS102 ... well as in non-alcoholic steatohepatitis (NASH) patients. ... is significantly sequestered in lung tissue and has ... tissue after oral administration. The Company will publish ...
Breaking Medicine Technology: